IIPM MANAGEMENT INSTITUTE
A
Though Samir Mehta was not successful in his bid to acquire Merck KGaA’s generic business, he still made headlines. When bigwigs like Actavis of Iceland and Ranbaxy pulled out of the race, citing stretched valuations, Mehta of Torrent hung in there till the very end. He made a bold bid of $6.3 billion, which was only cut short by Mylan Laboratories’ $6.7 billion bid. The Torrent fight was backed by three global private equity giants – UKbased Greater Pacific Capital and Tudor Investment Corporation, and US-based Fortress Group. The motivation driving Mehta was – had he been successful, Torrent Pharma would have emerged among the top five global generic players in the world.
For Complete IIPM Article, Click on IIPM Article
Source : IIPM Editorial, 2007
An IIPM and Professor Arindam Chaudhuri (Renowned Management Guru and Economist) Initiative